Concord Biotech Ltd: Intrinsic Value & Share Price Analysis

Last Updated: January 17, 2026, 8:57 am

All Competitor Stocks of Concord Biotech Ltd

Last Updated: December 27, 2025, 11:33 am

Below is a detailed analysis of the quarterly data for Concord Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Sales, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 204.00 Cr. (Jun 2025) to 247.00 Cr., marking an increase of 43.00 Cr..
• For Expenses, as of Sep 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 143.00 Cr. (Jun 2025) to 157.00 Cr., marking an increase of 14.00 Cr..
• For Operating Profit, as of Sep 2025, the value is 91.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Jun 2025) to 91.00 Cr., marking an increase of 30.00 Cr..
• For OPM %, as of Sep 2025, the value is 37.00%. The value appears strong and on an upward trend. It has increased from 30.00% (Jun 2025) to 37.00%, marking an increase of 7.00%.
• For Other Income, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Jun 2025) to 13.00 Cr., marking a decrease of 1.00 Cr..
• For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
• For Depreciation, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 18.00 Cr..
• For Profit before tax, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Jun 2025) to 86.00 Cr., marking an increase of 29.00 Cr..
• For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
• For Net Profit, as of Sep 2025, the value is 63.00 Cr.. The value appears strong and on an upward trend. It has increased from 43.00 Cr. (Jun 2025) to 63.00 Cr., marking an increase of 20.00 Cr..
• For EPS in Rs, as of Sep 2025, the value is 6.01. The value appears strong and on an upward trend. It has increased from 4.07 (Jun 2025) to 6.01, marking an increase of 1.94.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Last Updated: December 15, 2025, 3:56 am

Last Updated: September 5, 2025, 3:01 pm

Last Updated: December 4, 2025, 2:40 am

Below is a detailed analysis of the balance sheet data for Concord Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,815.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,802.00 Cr. (Mar 2025) to 1,815.00 Cr., marking an increase of 13.00 Cr..
• For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 3.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 1.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 194.00 Cr.. The value appears to be improving (decreasing). It has decreased from 219.00 Cr. (Mar 2025) to 194.00 Cr., marking a decrease of 25.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 2,021.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,034.00 Cr. (Mar 2025) to 2,021.00 Cr., marking a decrease of 13.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 790.00 Cr.. The value appears to be declining and may need further review. It has decreased from 795.00 Cr. (Mar 2025) to 790.00 Cr., marking a decrease of 5.00 Cr..
• For CWIP, as of Sep 2025, the value is 74.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 23.00 Cr..
• For Investments, as of Sep 2025, the value is 354.00 Cr.. The value appears strong and on an upward trend. It has increased from 335.00 Cr. (Mar 2025) to 354.00 Cr., marking an increase of 19.00 Cr..
• For Other Assets, as of Sep 2025, the value is 804.00 Cr.. The value appears to be declining and may need further review. It has decreased from 854.00 Cr. (Mar 2025) to 804.00 Cr., marking a decrease of 50.00 Cr..
• For Total Assets, as of Sep 2025, the value is 2,021.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,034.00 Cr. (Mar 2025) to 2,021.00 Cr., marking a decrease of 13.00 Cr..

Notably, the Reserves (1,815.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

After reviewing the key financial ratios for Concord Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
• For Diluted EPS (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
• For Cash EPS (Rs.), as of Mar 25, the value is 40.85. This value is within the healthy range. It has increased from 34.25 (Mar 24) to 40.85, marking an increase of 6.60.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 173.27. It has increased from 145.93 (Mar 24) to 173.27, marking an increase of 27.34.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 173.27. It has increased from 145.93 (Mar 24) to 173.27, marking an increase of 27.34.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 114.71. It has increased from 97.21 (Mar 24) to 114.71, marking an increase of 17.50.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 52.65. This value is within the healthy range. It has increased from 44.48 (Mar 24) to 52.65, marking an increase of 8.17.
• For PBIT / Share (Rs.), as of Mar 25, the value is 47.45. This value is within the healthy range. It has increased from 39.36 (Mar 24) to 47.45, marking an increase of 8.09.
• For PBT / Share (Rs.), as of Mar 25, the value is 47.40. This value is within the healthy range. It has increased from 39.11 (Mar 24) to 47.40, marking an increase of 8.29.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 35.65. This value is within the healthy range. It has increased from 29.13 (Mar 24) to 35.65, marking an increase of 6.52.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
• For PBDIT Margin (%), as of Mar 25, the value is 45.89. This value is within the healthy range. It has increased from 45.75 (Mar 24) to 45.89, marking an increase of 0.14.
• For PBIT Margin (%), as of Mar 25, the value is 41.36. This value exceeds the healthy maximum of 20. It has increased from 40.48 (Mar 24) to 41.36, marking an increase of 0.88.
• For PBT Margin (%), as of Mar 25, the value is 41.31. This value is within the healthy range. It has increased from 40.23 (Mar 24) to 41.31, marking an increase of 1.08.
• For Net Profit Margin (%), as of Mar 25, the value is 31.07. This value exceeds the healthy maximum of 10. It has increased from 29.96 (Mar 24) to 31.07, marking an increase of 1.11.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 30.96. This value exceeds the healthy maximum of 20. It has increased from 30.29 (Mar 24) to 30.96, marking an increase of 0.67.
• For Return on Networth / Equity (%), as of Mar 25, the value is 20.50. This value is within the healthy range. It has increased from 20.18 (Mar 24) to 20.50, marking an increase of 0.32.
• For Return on Capital Employeed (%), as of Mar 25, the value is 26.82. This value is within the healthy range. It has increased from 26.41 (Mar 24) to 26.82, marking an increase of 0.41.
• For Return On Assets (%), as of Mar 25, the value is 18.26. This value is within the healthy range. It has increased from 18.11 (Mar 24) to 18.26, marking an increase of 0.15.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.63 (Mar 24) to 0.64, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 6.17. This value exceeds the healthy maximum of 3. It has decreased from 6.30 (Mar 24) to 6.17, marking a decrease of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 4.87. This value exceeds the healthy maximum of 2. It has increased from 4.84 (Mar 24) to 4.87, marking an increase of 0.03.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.36. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 5.36, marking an increase of 4.49.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.19 (Mar 24) to 24.63, marking an increase of 1.44.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 21.48. This value is within the healthy range. It has increased from 19.75 (Mar 24) to 21.48, marking an increase of 1.73.
• For Earning Retention Ratio (%), as of Mar 25, the value is 75.37. This value exceeds the healthy maximum of 70. It has decreased from 76.81 (Mar 24) to 75.37, marking a decrease of 1.44.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 78.52. This value exceeds the healthy maximum of 70. It has decreased from 80.25 (Mar 24) to 78.52, marking a decrease of 1.73.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1,040.58. This value is within the healthy range. It has increased from 182.35 (Mar 24) to 1,040.58, marking an increase of 858.23.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 705.64. This value is within the healthy range. It has increased from 120.41 (Mar 24) to 705.64, marking an increase of 585.23.
• For Enterprise Value (Cr.), as of Mar 25, the value is 17,536.50. It has increased from 15,881.24 (Mar 24) to 17,536.50, marking an increase of 1,655.26.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.62 (Mar 24) to 14.61, marking a decrease of 1.01.
• For EV / EBITDA (X), as of Mar 25, the value is 31.84. This value exceeds the healthy maximum of 15. It has decreased from 34.13 (Mar 24) to 31.84, marking a decrease of 2.29.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.66 (Mar 24) to 14.61, marking a decrease of 1.05.
• For Retention Ratios (%), as of Mar 25, the value is 75.36. This value exceeds the healthy maximum of 70. It has decreased from 76.80 (Mar 24) to 75.36, marking a decrease of 1.44.
• For Price / BV (X), as of Mar 25, the value is 9.67. This value exceeds the healthy maximum of 3. It has decreased from 10.43 (Mar 24) to 9.67, marking a decrease of 0.76.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.66 (Mar 24) to 14.61, marking a decrease of 1.05.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

About the Company - Qualitative Analysis